• FTC and seven states request federal court hold Martin Shkreli in contempt for allegedly violating lifetime pharmaceutical industry ban.
  • Action enforces 2022 injunction, not a new prosecution over Daraprim price hike.
  • Allegations focus on Shkreli's post-ban activities, including Druglike venture; no hearing date set.

FTC and States Move to Enforce Ban

The Federal Trade Commission and seven states are asking a federal court to hold Martin Shkreli in contempt for allegedly violating his lifetime ban from the pharmaceutical industry, according to a filing announced today. The action, confirmed by FTC Commissioner Mark R. Meador, alleges repeated violations of a 2022 permanent injunction that prohibits Shkreli from directly or indirectly participating in the pharmaceutical business.

These are allegations, not a court finding. The distinction is critical: the FTC is seeking to enforce an existing order, not bringing new charges over the infamous Daraprim price increase that first landed Shkreli in legal jeopardy. The lifetime ban was affirmed by the Second Circuit in January 2024, solidifying its legal foundation.

A Pattern of Alleged Noncompliance

The contempt request marks the latest chapter in a long-running battle between regulators and Shkreli, who gained notoriety after Turing Pharmaceuticals (later Vyera) raised the price of toxoplasmosis treatment Daraprim by more than 4,000%. The original antitrust case, filed in January 2020, resulted in a $64.6 million disgorgement order and the industry ban. In January 2023, the FTC sought contempt over Shkreli's alleged failure to provide documents and sit for an interview regarding compliance—a dispute that appears to have escalated.

Today's filing alleges that Shkreli has engaged in prohibited industry participation, though the sources do not specify the exact nature of the violations. One focus is likely Druglike, a Web3 drug discovery platform Shkreli co-founded in July 2022. The venture has claimed it is "not a pharmaceutical company," but its activities—providing computing tools for designing potential therapeutic molecules—may fall within the injunction's broad language covering indirect participation. The FTC's 2023 compliance dispute already signaled concerns about Druglike's status.

Financial and Legal Stakes

For Shkreli personally, the contempt action could lead to fines or even imprisonment if the court finds willful violations. The FTC has not disclosed the specific sanctions it is seeking, and no hearing date has been set. The agency declined to comment beyond its public filing.

The corporate entities tied to Shkreli have largely collapsed. Vyera and Phoenixus AG entered bankruptcy in 2023, and an August 2023 agreement sold Daraprim and Vecamyl rights for $650,000—a fraction of the drug's former revenue potential. Druglike's financials are opaque; the reviewed sources show no revenue, profitability, or valuation data. Its relevance is legal, not commercial.

A Broader Enforcement Message

The case underscores the FTC's willingness to pursue individuals long after initial penalties are imposed. The original complaint was approved by a 5-0 vote in 2020, and the current Commission is continuing enforcement across leadership changes. While the action is U.S.-focused, Phoenixus's Swiss incorporation adds an international wrinkle to the corporate history.

Patients and payers may see little immediate impact, but the principle matters: a lifetime ban is only as strong as its enforcement. For generic manufacturers, the message is that anticompetitive conduct can carry personal, lasting consequences. Shkreli has previously argued that Druglike is a software company, not a pharmaceutical firm—a distinction that may now be tested in court.

What's Next

The immediate question is whether the court finds Shkreli in violation and what relief it orders. The FTC's announcement alone does not establish contempt; the burden is on the agency to prove its allegations. A ruling could clarify how industry bans apply to software and computational drug discovery, setting a precedent for future cases. For now, Shkreli's legal troubles are far from over.

Correction: An earlier version misstated the year of the Second Circuit's affirmation. It was January 2024, not 2023.